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In this study, the effect of ethylcellulose (EC) and 6 types of
hydroxypropylmethylcellulose (Methocel® K100M, K100MPRCR,
K15MPRCR, K4MPRCR, K4M PR and E4MCR) on release profile
of theophylline from matrix tablets was evaluated. Formulations
tablets were prepared by either wet granulation or direct
compression technique. The tablets were evaluated for physical
characteristics and in vitro release of drug was performed as
described in USP 30 ed. (Test 3). All formulations with cellulose
polymer produced tablets easily and with physicals characteristics
in accordance with official limits. Drug dissolution tests showed
that formulations with 15% of Methocel® K4MPR, 15% of
Methocel® K4MPRCR and 30% of Ethocel® N10STD, obtained by
direct compression method, complied with official specifications,
in terms of release profile and diffusion was the main mechanism
involved in theophylline delivery.
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INTRODUCTION
Theophylline is a methylxantine derivative very effective
in the chronic treatment of bronchial asthma and bronchos-
pastic reactions. Its therapeutic concentration range is narrow
(from 10 to 20 µg/mL) while toxicity usually appears at
concentrations above 20 µg/mL and the fluctuations of its
serum concentrations can result in variability in clinical
response (Parvez et al., 2004; Boswell-Smith, Cazzola, Page,
2006). Theophylline is an example of drug with a narrow
therapeutic range that may require drug monitoring both to
achieve therapeutic levels and minimize toxicity. In order to
overcome these problems, controlled release of theophylline
seems to be the most appropriate preparation (Boswell-Smith,
Cazzola, Page, 2006; Lordi, 1986; Siepmann, Peppas, 2001).
Several reviews on the use of polymers for
controlled release theophylline dosage forms had been
reported (Raslan, Maswadeh, 2006; Ikegami, Tagawa,
Osawa, 2006). Among the polymers available as possible
for matrix-forming materials and multiparticulate
systems, such as methacrylic resins, polysaccharidic gel,
and hydrophilic polymers, cellulose derivatives appear
particularly attractive (Jalal, Zmaily, Najib, 1989; Ford,
Rubinstein, Hogan, 1985; Siepmann, Peppas, 2001; Sung
et al., 1996; Lopes, Lobo, Costa, 2005).
Cellulose derivatives have been commonly used in
the formulation of hydro gel matrices for controlled drug
delivery. They are safe, nonionic and minimize interaction
problems when used in acidic, basic, or other electrolytic
system. They are suitable for preparing formulations with
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soluble or insoluble drugs and at high or low dosage levels.
Hydration of polymers results in the formation of a gel layer
that controls the release rate of drug (Ojoe et al., 2003;
Siepmann, Peppas, 2001; Costa, Souza Lobo, 1999).
The release of drug from controlled release tablets is
influenced by factors relating to the physicochemical
properties of the drug and to the dosage form. Factors
associated with polymers, such as polymer content,
molecular weight, concentration, degree of substitution,
and particle size, have been shown to have a significant
influence on drug release. However, the most important
factor that affects the drug release rate from cellulose
matrices are the polymer concentration and drug:polymer
ratio (Ford, Rubinstein, Hogan, 1985; Mitchell et al., 1993;
Xu, Sunada, 1995; Tahara, Yamamoto, Nishihata, 1995).
Despite the high number of papers on this subject, few
of them discuss the efficiency of cellulose polymers available
commercially. Therefore, the aim of the present work was to
evaluate the suitability of different cellulose polymers to pre-
pare theophylline matrix tablets able to assure controlled and
well reproducible drug release profiles, also to verify release
performances when soluble and insoluble fillers are used, as
well as to study drug release profiles by fitting to kinetic
models. The cellulose polymers hydroxypropylmethylcellulose
(HPMC) and ethylcellulose (EC), the diluents lactose
monohydrate and tribasic calcium phosphate, and the lubricant
magnesium stearate were studied.
MATERIAL AND METHODS
Reagents and Materials
Anhydrous theophylline (Ariston -98060278);
hydroxypropylmethylcellulose - Methocel® K100M,
Methocel® K100MPRCR, Methocel® K15MPRCR,
Methocel® K4MPRCR, Methocel® K4M PR and
Methocel® E4MCR (Dow Chemical, obtained from
Colorcon Brazil), ethylcellulose - Ethocel® N10STD
(Dow Chemical), lactose M200 (Henrifarma), tribasic
calcium phosphate (Merck), magnesium stearate
(Quimibrás Brazil), siliceous dioxide (Henrifarma) and
polyvinyl pyrrolidone (PVP) - Kollidon® 30 (Basf).
Anhydrous theophylline, 99.80% donated by Ariston, was
used as standard in quantitative determinations.
Monobasic potassium phosphate (Merck) and
hydrochloric acid 37% (Merck) were of analytic reagent
grade. All other reagents were special grade commercial
preparations.
Preparation of Theophylline HPMC and EC Matrix
Tablets
Tablet formulations were prepared by direct-
compression or wet granulation methods.
Batches from HPMC 1 to 5 were prepared by wet
granulation and batches from HPMC 6 to 11 and EC were
directly compressed. A schematic illustration of the
preparation method of the sustained-release theophylline
tablets is shown in Figure 1. For the direct compression
method, the steps 3, 4, 5, and 6 were not included. The
composition of the prepared tablets is listed in Tables I, II
and III. Then, tablets (diameter, 10 mm) containing
200 mg of theophylline were obtained by the Fabbe single
punch machine. The compression forces were adjusted for
the different formulations to obtain similar tablet
hardness.
FIGURE 1 – Schematic illustration of theophylline tablets preparation.
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Determination of theophylline from HPMC matrix
tablets
Theophylline content in tablets was determined by
spectrophotometric analysis at 270 nm using a Shimadzu
UV 1601 analyzer. The tablets were powdered and aliquots
theoretically corresponding to 200 mg of theophylline were
transferred to 200 mL volumetric flasks and mixtured with
200 mL of distilled water, in an ultrasound apparatus, for
5 minutes. After centrifugation, samples of 1 mL were
taken, diluted to 100 mL with simulated gastric fluid (pH
1.2). Simultaneously, a 10 µg/mL theophylline standard
solution was recorded. The assay of theophylline in
formulations was carried out in triplicate.
Physical tests
The compressed tablets were characterized by their
physical properties. The average tablet weight was
determined from 20 tablets (USP, 2007).
Hardness of the tablets was tested using a Pharma
Test PTB 311 hardness tester. Friability of the tablets was
TABLE I – Composition of hydroxypropylmethylcellulose (Methocel® K100M) matrix formulations prepared by wet
granulation
Contents (%) HPMC 1 HPMC 2 HPMC 3 HPMC 4 HPMC 5
Theophylline 66.67 66.67 66.67 66.67 66.67
Methocel® K100M 10.00 20.00 10.00 20.00 10.00
Magnesium stearate 3.00 3.00 3.00 3.00 0.50
Kollidon® 30 10.00 10.00 10.00 10.00 10.00
Calcium phosphate 0.00 0.00 10.33 0.33 0.00
Lactose 10.33 0.33 0.00 0.00 12.83
TABLE III - Composition of hydroxypropylmethylcellulose (Methocel® E4MCR; K100M) and ethylcellulose (Ethocel®
N10STD) matrix formulations prepared by direct compression
Contents (%) HPMC 10 HPMC 11 EC
Theophylline 66.67 66.67 66.67
Methocel® E4MCR 31.33 0.00 0.00
Methocel® K100M 0.00 31.33 0.00
Ethocel® N10STD 0.00 0.00 31.33
Magnesium stearate 0.50 0.50 0.50
Lactose 1.50 1.50 1.50
TABLE II - Composition of hydroxypropylmethylcellulose (Methocel® K4MPR; K4MPRCR; K100MPRCR;
K15MPRCR) matrix formulations prepared by direct compression
Contents (%) HPMC 6 HPMC 7 HPMC 8 HPMC 9
Theophylline 66.67 66.67 66.67 66.67
Methocel® K4MPR 15.00 0.00 0.00 0.00
Methocel® K4MPRCR 0.00 15.00 0.00 0.00
Methocel® K100MPRCR 0.00 0.00 15.00 0.00
Methocel® K15MPRCR 0.00 0.00 0.00 15.00
Magnesium stearate 0.50 0.50 0.50 0.50
Lactose 17.83 17.83 17.83 17.83
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determined in an Etica friabilator. Tablet friability was
calculated as the percentages of weight loss of 20 tablets
after 100 rotations (USP, 2007).
In vitro dissolution tests
Dissolution measurements were carried out in a USP
30 ed. method described for theophylline extended-release
capsules (test 3) at 37 ± 0.5 °C, with paddle at 50 rpm and
900 mL of dissolution medium using pH 1.2 simulated
gastric fluid for the first 1 h and pH 7.5 of simulated intes-
tinal fluid for the following 6 h. Samples of 10 mL were
taken from the dissolution medium at appropriate intervals
and the absorbancies were measured by UV
spectrophotometer at 270 and 271 nm. These values of the
drug released from tablets were plotted in graphs of drug
released versus time. For elucidation of the drug release
mechanism, dissolution data were analyzed using zero
order, first order and Higuchi equations, with linear
regression (Chambin et al., 2004; Manadas, Pina, Veiga,
2002).
RESULTS AND DISCUSSION
Theophylline tablets provided good weight
uniformity, according to 7.5% of variation, referring to
tablets with weight between 200 mg and 300 mg (United
States Pharmacopoeia, 2007). All the formulations were
within the USP limits for friability (< 1% weight loss),
hardness, diameter and height (Table IV). The tablets
showed no physical defects such as capping or lamination
(USP, 2007).
Cellulose polymers showed to be efficient to control
the theophylline release from the tablets. As polymer
percentages increased in tablet formulations, the amounts
of drug delivered decreased in dissolution tests (Figure 2).
The effect of fillers on drug release was observed in
formulations using 10% and 20% of Methocel® K100M
with lactose (HPMC 1 and HPMC 2) or tribasic calcium
phosphate (HPMC 3 and HPMC 4). Higher quantities of
drug dissolved were obtained from formulations with
soluble fillers (Figure 2).
Tablets with 10% of Methocel® K100M released
about 92% of the drug after 420 min when 0.5% of
magnesium stearate and lactose were used (HPMC 5);
therefore the addition of 3.0% of magnesium stearate to the
similar formulation (HPMC 1) resulted in 74% of dissolved
drug (Figure 2). According to Hussain, York, Timmins
(1992) dissolution rate retardation in the presence of
magnesium stearate has been attributed to the formation of
a hydrophobic film on the surface of the particles. This
hydrophobic barrier might effectively result in reduced
wettability and reduced particle surface area available for
dissolution.
Dürig, Venkatesh, and Fassihi (1999) related that
magnesium stearate is a critical erosion-controlling
excipient, particularly if it is used over 1.0%. In an
investigation of controlled release tablets using HPMC,
they observed that high levels of magnesium stearate
(> 2.5%), influenced the balance between radial and axial
TABLE IV - Tablets data from physicochemical analyses and drug content. Relative standard deviations (%) are in
parenthesis
Formulation Weight  Drug content Friability Hardness Diameter Height
(mg) % w/w % (kgf) (mm) (mm)
HPMC 1 303.16 (5.87) 103.44 0.61 4.59 (0.06) 10.07 (0.03) 4.34 (0.27)
HPMC 2 300.60 (5.99) 99.07 0.82 4.64 (0.11) 10.06 (0.01) 4.09 (0.09)
HPMC 3 298.90 (1.50) 103.39 0.22 4.59 (0.11) 9.92 (0.41) 4.12 (1.33)
HPMC 4 302.73 (4.02) 101.01 0.31 6.78 (0.07) 10.04 (0.02) 4.12 (0.02)
HPMC 5 310.40 (6.19) 93.38 0.42 5.20 (0.81) 10.03 (0.02) 3.96 (0.11)
HPMC 6 303.79 (8.88) 97.60 0.75 9.44 (0.20) 10.03 (0.03) 3.86 (0.15)
HPMC 7 296.48 (9.45) 96.78 0.81 9.03 (0.33) 10.03 (0.05) 3.68 (0.17)
HPMC 8 300.42 (8.75) 98.42 0.56 7.29 (0.12) 10.02 (0.03) 3.96 (0.33)
HPMC 9 303.58 (9.54) 96.41 0.86 9.95 (0.39) 10.03 (0.05) 3.60 (0.16)
HPMC 10 292.35 (13.41) 95.01 0.64 7.35 (0.29) 10.05 (0.02) 4.33 (0.29)
HPMC 11 296.55 (8.90) 90.66 0.44 8.72 (0.43) 10.02 (0.01) 4.38 (0.28)
EC 295.56 (10.46) 94.74 0.72 5.56 (0.29) 10.07 (0.03) 4.49 (0.32)
HPMC – Formulations with hydroxypropylmethylcellulose; EC – formulation with ethylcellulose
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erosion rates, leading to lower percentages of drug
dissolved. This fact is of particular importance when drugs
with poor solubility, like theophylline, are formulated with
high amounts of this lubricant, because, as stated by Sung
et al. (1996), they are released preferentially by erosion
while soluble drugs can dissolve and diffuse through the
hydrated gel layer (Reza, Quadir, Haider, 2003; Ibrhim,
Daes, Bangudu, 2000).
The dissolution assay results demonstrated that the
amount of polymer used was very important to control the
drug release. According to Figure 3, the theophylline
release profiles from formulations with 15% of Methocel®
K4MPR (HPMC 6) and Methocel® K4MPRCR (HPMC
7) was similar. Both of them showed a slight difference in
their dissolution profiles and higher percentage of drug
dissolved than the other formulations containing 15% of
Methocel® K100MPRCR (HPMC 8) and K15MPRCR
(HPMC 9) polymers. The letters CR of the Methocel®
refers to controlled-release grade, represented by ultra-fine
particle size materials, that is able to hydrate fast, leading
to effective formation of protective gel barrier. In this
research, however, no difference regarding theophylline
release was found when CR polymers were used (Figure 3).
In addition, Figure 3 shows the influence of polymer
viscosity on the theophylline release by comparing HPMC
6 and HPMC 7 with HPMC 8 and HPMC 9.
However, in our work, no significant differences were
observed between the release profiles from HPMC 8 and
HPMC 9 formulations, with 15% of Methocel®
K100MPRCR and 15% of Methocel® K15MPRCR,
respectively. Similar reports were found in literature by
Sung et al. (1996) that reported no differences on the
adinazolam mesilate release between formulations
produced with Methocel® K15M and Methocel® K100M.
They concluded that there were limitations in the polymer
viscosity when small amounts are used.
Methocel® K and E possess different ratios of
hydroxypropyl and methyl substitution, which influences
properties such as organic solubility and thermal gelation
temperature of aqueous solutions. The texture and the
strength of gel produced by these polymers vary with the
type, viscosity grade, and concentration of polymer used.
The size, shape and ionization of the drug affect its
diffusion through the gel layer. The drug diffusion through
most types of polymeric systems is often best described by
Fickian diffusion (Patel, Patel, 2007).
The viscosity of the polymers had a dominant role as
controlling factors on kinetics of drug release. In general,
the strength of the gel increases with increasing molecular
weight (Patel, Patel, 2007). K100M is the higher molecular
weight polymer, consequently, in the systems with different
viscosity grades of K-Methocel® products, the release rates
FIGURE 2 - Effect of polymer type, excipient type and lubricant concentration on release of theophylline from tablet
formulations.
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decreased with increasing polymer molecular weights,
according to the Figure 4.
The substitution’s groups are essential for the
polymer hydration of controlled release systems and the
choice of polymer is very important because the fast
polymer hydration is needed to form the gel barrier, and this
gel layer should be sufficiently strong to control the drug
and water diffusion. For this reason, the K-polymers
FIGURE 3 - Effect of polymer type, excipient type and lubricant concentration on release of theophylline from tablet
formulations.
FIGURE 4 - Effect of polymer type, lactose excipient and lubricant concentration on release of theophylline from tablet
formulations.
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hydrated result on stronger barrier than those formed by E-
polymers. Methocel® K has the highest ratio of
hydroxypropoxyl to methoxyl substitution.
Comparing HPMC 10, HPMC 11 and EC
formulations, when 30% of polymer was used (Methocel®
E4MCR, K100M and Ethocel® N10STD), higher
quantities of drug dissolved were obtained from tablets
formulated with Ethocel® N10STD (Figure 4).
Formulations HPMC 6, HPMC7 and EC
corresponding respectively to Methocel® K4MPR (15%),
Methocel® K4MPRCR (15%) and Ethocel® N10STD
(30%) showed amount of theophylline release (%)
according to specifications in Test 3, USP 30. The release
data of matrix tablets were fitted into various mathematical
models (zero, first, Higuchi’s square root equation) to
evaluate the kinetics and mechanism of drug release from
the tablets. The model that best fits the release data is
selected based on the correlation coefficient (r) value in
various models. The model that gives high ‘r’ value is
considered as the best fit of the release data. The ‘r’ values
in zero, first order and Higuchi models are given in Table
V. It was found Higuchi as a kinetic model that best fitted
in the majority of the formulations tested and for the others,
first-order (Chowdary, Mohapatra, Murali Krishna, 2006).
Drug release from matrix tablets, in general, becomes
progressively slower with time, like Higuchi’s model, in
which the amount of drug released is proportional to the
square root of time. Kinetic models which fit zero order and
Higuchi are more suitable for controlled release
formulations, while first order model is more appropriate
for conventional tablets (Chowdary, Mohapatra, Murali
Krishna, 2006).
The analysis of the Td50% and Kd values (Table V)
revealed that the release kinetics is mainly affected by
cellulose polymer and excipient type (lactose and calcium
phosphate) content.
CONCLUSION
The mixing formulation of granules formed with
theophylline and cellulose polymers like Methocel® and
Ethocel® to prepare oral controlled release tablets showed
appropriate compression.
Theophylline tablets prepared with Methocel®
K100M polymer, showed influence on percentage of drug
release when amounts of 10% and 20% of polymer was
used, also the type of diluents (soluble and insoluble) and
amount of lubricant showed significant differences. Higher
quantities of drug dissolved were obtained from
formulations using 10% of Methocel® K100M with lactose
and 0.5% of magnesium stearate.
The studies showed that the theophylline release
profiles from formulations with 15% of Methocel®
K4MPR and Methocel® K4MPRCR was similar and no
difference regarding theophylline release was found when
CR polymers were used. Formulations with 15% of
Methocel® K4MPR or 15% of Methocel® K 4MPRCR
showed higher amount percentage of drug dissolved if
comparing with formulations containing 15% of
K100MPRCR or 15% of K15MPRCR polymers.
The hydrated K-polymers result on stronger barrier
than those formed by E-polymers, for this reason
Methocel® K showed lower amount percentage of drug
dissolved if comparing with Methocel E.
TABLE V - Kinetic assessment: correlation coefficient (r) of kinetics model, dissolution rate (kd) half-life of release (Td50%)
Formulations Coefficients of correlation (r)
Zero-order First-order Higuchi Kd (min-1 ) Td50% (min)
HPMC 1 0.8404 0.9664 0.9709 0.0408 093.49
HPMC 2 0.8519 0.9216 0.9655 0.0330 194.31
HPMC 3 0.8705 0.9603 0.9753 0.0305 193.62
HPMC 4 0.9317 0.9679 0.9890 0.0220 490.02
HPMC 5 0.8705 0.9767 0.9930 0.0358 176.49
HPMC 6 0.8687 0.9890 0.9877 0.0032 079.91
HPMC 7 0.8763 0.9890 0.9868 0.0035 080.34
HPMC 8 0.9324 0.9839 0.9946 0.0285 314.96
HPMC 9 0.9330 0.9878 0.9983 0.0247 417.51
HPMC 10 0.9365 0.9695 0.9973 0.0211 551.91
HPMC 11 0.9528 0.9726 0.9959 0.0161 995.56
EC 0.9852 0.6021 0.9562 0.0023 184.10
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The fit to the Higuchi model indicated that the drug
release mechanism from these polymers matrices was
controlled by the diffusion.
Dissolution rate was higher for EC than for HPMC
excipients, but both formulations showed adequate
chemical analyses data and these results demonstrated that
Methocel® and Ethocel® were a useful material for a
controlled release tablet.
RESUMO
Desenvolvimento e avaliação de comprimidos
matriciais de teofilina baseados em ésteres da celulose
Os efeitos das variáveis das formulações na liberação da
teofilina a partir da hidroxipropilmetilcelulose (HPMC)
e etilcelulose (EC) em comprimidos matriciais foram es-
tudados. Formulações de comprimidos foram preparadas
pelos métodos da granulação úmida ou compressão direta
usando diferentes viscosidades de HPMC. Propriedades
físico-químicas dos comprimidos e liberação do fármaco
foram estudadas conforme dissolução descrita no Teste 3
da Farmacopéia Americana 30ed. Ensaios “in vitro”
mostraram que as formulações com 15% de Methocel®
K4MPR, 15% de Methocel® K4MPRCR e 30% de
Ethocel® N10STD obtidas por compressão direta apresen-
taram bom perfil de liberação de teofilina e a difusão foi
o principal mecanismo envolvido na liberação.
UNITERMOS: Teofilina. Liberação modificada. Matri-
zes. Hidroxipropilmetilcelulose. Etilcelulose.
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